Your session is about to expire
← Back to Search
Surgery vs Stereotactic Ablative Radiotherapy for Lung Cancer (STABLE-MATES Trial)
STABLE-MATES Trial Summary
This trial is testing whether a more targeted form of radiation therapy called SABR is more effective than the standard SR radiation therapy in treating operable stage I NSCLC.
STABLE-MATES Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSTABLE-MATES Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2013 Phase 3 trial • 397 Patients • NCT00004054STABLE-MATES Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Frequently Asked Questions
Could you explain the age limit for this particular clinical trial?
"According to the guidelines for this trial, any person aged 18 or older but not yet turned 100 is eligible to participate."
Could you please summarize the risks associated with Radiation therapy?
"Radiation therapy is considered safe, and has received a score of 3 from our team at Power."
Are we currently able to enroll new participants in this research?
"The correct, per the information available on clinicaltrials.gov. This particular clinical trial was posted on 7/1/2015 and was most recently updated on 10/5/2022. The study is currently enrolling 272 patients across 22 locations."
Do I fit the patient profile for this particular research project?
"This trial is looking for 272 individuals above the age of 18 that have non-small cell lung carcinoma (nsclc). Most notably, patients must meet the following requirements: Radiographic findings that are consistent with non-small cell lung cancer, including lesions with ground glass opacities and a solid component that is 50% or greater. Those with ground glass opacities and a solid component that is less than 50% will be excluded., All clinically suspicious mediastinal N1, N2, or N3 lymph nodes (> 1 cm short-axis dimension on CT scan and/or positive on PET scan) confirmed negative"
Share this study with friends
Copy Link
Messenger